Compared to the general population, older adults are more at risk of experiencing adverse drug reactions. Why is this the case, and what does this mean for pharmacovigilance?

In focus / 29 October 2024

AI holds potential to transform pharmacovigilance. But navigating the risks requires critical assessment. This article explores AI's evolving role in medicines safety.

Research / 22 October 2024

Pharmacovigilance monitors the safety of the medicines we use, but what about those that get into our environment?

In focus / 15 October 2024

The READUS-PV statement is the first-ever guide for reports of disproportionality analyses that are replicable, reliable, and reproducible.

Research / 07 October 2024